Insulin Pricing

The co-chairs of the Diabetes Caucus, Congresswoman Diana DeGette (D-CO) and Congressman Tom Reed (R-NY), are conducting an inquiry to determine the causes of rising prices for insulin, a life-saving drug for millions of Americans living with diabetes. Average insulin prices nearly tripled between 2002 and 2013, and many patients are also facing high prices due to steep deductibles, coinsurance and formulary exclusions.

Taking Action

Representatives DeGette and Reed sent letters in June requesting meetings from three key stakeholders: the Pharmaceutical Research and Manufacturers of America (PhRMA), the Pharmaceutical Care Management Association and America’s Health Insurance Plans. These are the major trade associations for the pharmaceutical industry, the pharmacy benefit managers and the health insurance industry, respectively.

An Ongoing Effort

After meeting with top officials from these three organizations, the members released key findings summarizing what was discussed in these meetings and an additional meeting with the American Diabetes Association. These key insights now serve as a launching pad for further conversations and fact-finding on this complex problem. The goal is to collect all the information necessary to develop meaningful, bipartisan policies that will make a difference for people with diabetes and their families.

Representatives DeGette and Reed will continue their search for answers and solutions to the question of rising insulin prices. As their inquiry continues, this page will be updated with further documents and news links.


For more information, email


Letter to FDA on Barriers to Developing Biosimilar Insulins

Letter to the Endocrine Society on Insulin Prescribing Practices

Response from the Endocrine Society

Value-Based Contract RFI 

Letter to Pharmaceutical Care Management Association (PCMA) on Formularies

Letter to America's Health Insurance Plans (AHIP) on Formularies

Letter to Novo Nordisk on Drug Discount Programs

Letter to Eli Lilly on Drug Discount Programs

Letter to Sanofi on Drug Discount Programs

QFR Responses E&C Drug Supply Chain Hearing

Value-Based Contracting Key Findings


In The News

In Bipartisan Insulin Pricing Inquiry, DeGette and Reed Explore Value-Based Contracting Options

In Ongoing Insulin Pricing Inquiry, Caucus Seeks Information on Formularies and Drug Discount Programs

DeGette, Reed Taking Next Steps in Insulin Price Inquiry

Washington Post: Lawmakers Make Bipartisan Push to Understand the Soaring Price of a Lifesaving Drug

Caucus Seeks Views on Value-Based Contracting for Insulin